Melanocytic Neoplasm

Observed

← altered in cohorts of

TTN

388 / 470 cases (83 %) · ssm · TCGA-SKCM · largest of 14 cohorts

—

Observed

← altered in cohorts of

MUC16

377 / 470 cases (80 %) · ssm · TCGA-SKCM · largest of 14 cohorts

—

Observed

← altered in cohorts of

ANK3

375 / 470 cases (80 %) · ssm · TCGA-SKCM · largest of 11 cohorts

—

Observed

← altered in cohorts of

CCN4

62 / 80 cases (78 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SLC45A4

61 / 80 cases (76 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CDKN2B

356 / 470 cases (76 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

AARD

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

AGO2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ANXA13

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ASAP1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ATAD2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

C8orf76

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CCN3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CHRAC1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

COL14A1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

COLEC10

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CYRIB

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DENND3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DEPTOR

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DERL1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DSCC1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EFR3A

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EIF3H

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ENPP2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EXT1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

FAM83A

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

FAM91A1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

FBXO32

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GPR20

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GRHL2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GSDMC

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

HAS2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

HHLA1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

KCNK9

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

KCNQ3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

KHDRBS3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

KLHL38

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

LRATD2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

LRRC6

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MAL2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MED30

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MRPL13

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MTBP

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MTSS1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MYC

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

NDRG1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

NDUFB9

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

NSMCE2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

NTAQ1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

OC90

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PHF20L1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PLEC

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

POU5F1B

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PTK2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PTP4A3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

RAD21

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

RNF139

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SAMD12

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SLA

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SLC30A8

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SNTB1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SQLE

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ST3GAL1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TAF2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TATDN1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TBC1D31

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TMEM65

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TMEM71

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TNFRSF11B

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TRAPPC9

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TRIB1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TRMT12

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

TRPS1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

UTP23

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

WASHC5

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZFAT

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZHX1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZHX1-C8orf76

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZHX2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZNF572

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DMBT1

352 / 470 cases (75 %) · ssm · TCGA-SKCM · largest of 8 cohorts

—

Observed

← altered in cohorts of

FREM1

352 / 470 cases (75 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

MTAP

351 / 470 cases (75 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

DNAH5

350 / 470 cases (74 %) · ssm · TCGA-SKCM · largest of 14 cohorts

—

Observed

← altered in cohorts of

CPQ

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DCSTAMP

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

EXOSC4

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

GPAA1

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

MFSD3

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

OSR2

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PPP1R16A

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

PYCR3

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

RHPN1

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

RNF19A

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SLC25A32

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

VPS13B

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

VPS28

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZNF16

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ZNF623

59 / 80 cases (74 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

DMRTA1

346 / 470 cases (74 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

PCLO

342 / 470 cases (73 %) · ssm · TCGA-SKCM · largest of 13 cohorts

—

Observed

← altered in cohorts of

TAF1L

342 / 470 cases (73 %) · ssm · TCGA-SKCM · largest of 3 cohorts

—

Observed

← altered in cohorts of

ADAMTSL1

341 / 470 cases (73 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA16

341 / 470 cases (73 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNE

341 / 470 cases (73 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

SYNE1

341 / 470 cases (73 %) · ssm · TCGA-SKCM · largest of 9 cohorts

—

Observed

← altered in cohorts of

IFNA7

340 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA14

339 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA4

339 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

MGAM

339 / 470 cases (72 %) · ssm · TCGA-SKCM · largest of 8 cohorts

—

Observed

← altered in cohorts of

PCDH15

339 / 470 cases (72 %) · ssm · TCGA-SKCM · largest of 11 cohorts

—

Observed

← altered in cohorts of

BNC2

338 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

ELAVL2

338 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

FOCAD

338 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA21

338 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA6

338 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

SH3GL2

337 / 470 cases (72 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA10

336 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA13

336 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNB1

336 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNW1

336 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

CER1

335 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA1

335 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA17

335 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA2

335 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA5

335 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

KLHL9

335 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

MPDZ

335 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

SAXO1

335 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

CNTLN

334 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

HACD4

334 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IFNA8

334 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

TYRP1

334 / 470 cases (71 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

TACC2

333 / 470 cases (71 %) · ssm · TCGA-SKCM · largest of 8 cohorts

—

Observed

← altered in cohorts of

CCDC171

331 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

DOCK8

330 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

MLLT3

330 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

SLC24A2

330 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

TEK

330 / 470 cases (70 %) · ssm · TCGA-SKCM · largest of 2 cohorts

—

Observed

← altered in cohorts of

TTC39B

330 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

HAUS6

329 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

NFIB

329 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

PSIP1

329 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

ZDHHC21

329 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

ACER2

328 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

DMRT3

328 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

LURAP1L

328 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

PLIN2

328 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

RPS6

328 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

SMARCA2

328 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

SNAPC3

328 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

DENND4C

327 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

GLIS3

327 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

INSL6

327 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

RRAGA

327 / 470 cases (70 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

DMRT1

325 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IZUMO3

325 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

JAK2

325 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

GLDC

324 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

KDM4C

324 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

RCL1

324 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

INSL4

323 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

LINGO2

323 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

CD274

322 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

KIAA2026

322 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

SORCS3

322 / 470 cases (69 %) · ssm · TCGA-SKCM · largest of 5 cohorts

—

Observed

← altered in cohorts of

TPD52L3

322 / 470 cases (69 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

DMRT2

321 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

ERMP1

321 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

IL33

321 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

KCNV2

321 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

PLGRKT

321 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

RLN1

321 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

DMAC1

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

DNAH8

320 / 470 cases (68 %) · ssm · TCGA-SKCM · largest of 12 cohorts

—

Observed

← altered in cohorts of

KANK1

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

PDCD1LG2

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

RANBP6

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

RFX3

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

RIC1

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

RLN2

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

SLC1A1

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

TUSC1

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

VLDLR

320 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

CYP2C19

319 / 470 cases (68 %) · ssm · TCGA-SKCM · largest of 2 cohorts

—

Observed

← altered in cohorts of

IFT74

319 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

LRRC19

319 / 470 cases (68 %) · ssm · TCGA-SKCM

—

Observed

← altered in cohorts of

PCDHAC2

184 / 346 cases (53 %) · ssm · skcm_tcga_pub_2015

—

Observed

← altered in cohorts of

GNAQ

40 / 80 cases (50 %) · ssm · uvm_tcga · largest of 3 cohorts

—

Observed

← altered in cohorts of

PRB2

38 / 78 cases (49 %) · ssm · skcm_broad_brafresist_2012

—

Observed

← altered in cohorts of

PCDHGC5

164 / 346 cases (47 %) · ssm · skcm_tcga_pub_2015

—

Observed

← altered in cohorts of

GNA11

36 / 80 cases (45 %) · ssm · uvm_tcga · largest of 3 cohorts

—

Observed

← altered in cohorts of

BRAF

301 / 696 cases (43 %) · ssm · mel_mskimpact_2020 · largest of 15 cohorts

—

Observed

← altered in cohorts of

CRIPAK

31 / 78 cases (40 %) · ssm · skcm_broad_brafresist_2012

—

Observed

← altered in cohorts of

PRG4

31 / 78 cases (40 %) · ssm · skcm_broad_brafresist_2012

—

Observed

← altered in cohorts of

LRP1B

182 / 469 cases (39 %) · ssm · skcm_tcga_gdc · largest of 13 cohorts

—

Observed

← altered in cohorts of

TCHH

29 / 78 cases (37 %) · ssm · skcm_broad_brafresist_2012

—

Observed

← altered in cohorts of

TRIOBP

29 / 78 cases (37 %) · ssm · skcm_broad_brafresist_2012

—

Observed

← altered in cohorts of

PTPRT

254 / 696 cases (36 %) · ssm · mel_mskimpact_2020 · largest of 8 cohorts

—

Observed

Melanocytic Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 214show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal antibody 256 trials (94 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	256	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 231 trials (82 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	231	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 226 trials (51 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	226	Observed	clinicaltrials	graph →
→ investigated in trials for	Aldesleukinother 135 trials (15 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	135	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 118 trials (22 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	118	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 84 trials (15 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	84	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 67 trials (6 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	67	Observed	clinicaltrials	graph →
→ investigated in trials for	Trametinibsmall molecule 67 trials (17 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	67	Observed	clinicaltrials	graph →
→ investigated in trials for	Vemurafenibsmall molecule 64 trials (4 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	64	Observed	clinicaltrials	graph →
→ investigated in trials for	Dacarbazinesmall molecule 60 trials (4 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	60	Observed	clinicaltrials	graph →
→ investigated in trials for	Dabrafenibsmall molecule 58 trials (13 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 40 trials (6 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 39 trials (9 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	39	Observed	clinicaltrials	graph →
→ investigated in trials for	Binimetinibsmall molecule 34 trials (14 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 30 trials (5 active) · roll-up of the cancer and its descendants	—	—	Melanocytic Neoplasm	30	Observed	clinicaltrials	graph →

Melanocytic Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 214show all (up to 200)

→ investigated in trials for

Pembrolizumabmonoclonal antibody

256 trials (94 active) · roll-up of the cancer and its descendants

—

256

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

231 trials (82 active) · roll-up of the cancer and its descendants

—

231

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

226 trials (51 active) · roll-up of the cancer and its descendants

—

226

Observed

→ investigated in trials for

Aldesleukinother

135 trials (15 active) · roll-up of the cancer and its descendants

—

135

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

118 trials (22 active) · roll-up of the cancer and its descendants

—

118

Observed

→ investigated in trials for

Fludarabinesmall molecule

84 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temozolomidesmall molecule

67 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trametinibsmall molecule

67 trials (17 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vemurafenibsmall molecule

64 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dacarbazinesmall molecule

60 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dabrafenibsmall molecule

58 trials (13 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

40 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

39 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Binimetinibsmall molecule

34 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

30 trials (5 active) · roll-up of the cancer and its descendants

—

Observed

Melanocytic Neoplasm studied in …STUDIED_INderived10 of 3,258show all (up to 200)
→ studied in	NCT00003641Phase 3 · completed High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04708418Phase 2 · active not recruiting A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma · condition mapped PROBABILISTIC · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06466434NA · recruiting Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma · condition mapped CURATED_BROADER · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07005297not yet recruiting Clinical Genetics Branch Eligibility Screening Survey · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07224425Phase 1 · recruiting A Study of BI 3810944 in Patients With Advanced Cancer · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07281924Phase 1/Phase 2 · recruiting Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis · condition mapped CURATED_BROADER · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07328516enrolling by invitation Natural History Study of Early Life Exposures in Agriculture (ELEA) · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07847359Phase 2 · recruiting Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07848243Phase 2 · recruiting Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →

Melanocytic Neoplasm studied in …STUDIED_INderived10 of 3,258show all (up to 200)

→ studied in

NCT00003641Phase 3 · completed

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT02465060Phase 2 · active not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT04708418Phase 2 · active not recruiting

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma · condition mapped PROBABILISTIC · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT06466434NA · recruiting

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma · condition mapped CURATED_BROADER · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT07005297not yet recruiting

Clinical Genetics Branch Eligibility Screening Survey · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT07224425Phase 1 · recruiting

A Study of BI 3810944 in Patients With Advanced Cancer · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT07281924Phase 1/Phase 2 · recruiting

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis · condition mapped CURATED_BROADER · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT07328516enrolling by invitation

Natural History Study of Early Life Exposures in Agriculture (ELEA) · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT07847359Phase 2 · recruiting

Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)

—

Observed

→ studied in

NCT07848243Phase 2 · recruiting

Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes · condition mapped ONTOLOGY_EXACT · 3,258 trials mapped (760 active)

—

Observed